Goldenwell Biotech (GWLL) Debt to Equity (2023 - 2025)
Goldenwell Biotech's Debt to Equity history spans 3 years, with the latest figure at -$1.17 for Q1 2025.
- For Q1 2025, Debt to Equity changed N/A year-over-year to -$1.17; the TTM value through Mar 2025 reached -$1.17, changed N/A, while the annual FY2024 figure was -$2.02, 326.79% down from the prior year.
- Debt to Equity reached -$1.17 in Q1 2025 per GWLL's latest filing, up from -$2.02 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.89 in Q4 2023 to a low of -$2.02 in Q4 2024.
- Average Debt to Equity over 3 years is -$0.77, with a median of -$1.17 recorded in 2025.
- The largest YoY upside for Debt to Equity was 326.79% in 2024 against a maximum downside of 326.79% in 2024.
- A 3-year view of Debt to Equity shows it stood at $0.89 in 2023, then plummeted by 326.79% to -$2.02 in 2024, then skyrocketed by 42.12% to -$1.17 in 2025.
- Per Business Quant, the three most recent readings for GWLL's Debt to Equity are -$1.17 (Q1 2025), -$2.02 (Q4 2024), and $0.89 (Q4 2023).